MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial

被引：0
|
作者：
Tourbah, A. [1 ,2 ]
Lebrun-Frenay, C. [3 ]
Edan, G. [4 ]
Clanet, M. [5 ]
Papex, C. [6 ]
Vukusic, S. [7 ]
De Sesze, J. [8 ]
Debouverie, M. [9 ]
Gout, O. [10 ]
Clavelou, P. [11 ]
Defer, G. [12 ]
Laplaud, D. [13 ]
Moreau, T. [14 ]
Labauge, P. [15 ]
Brochet, B. [16 ]
Sedel, F. [17 ]
Pelletier, J. [18 ]
机构：
[1] URCA, CHU Reims, Serv Neurol, Neurol, Reims, France
[2] URCA, CHU Reims, Fac Med, Reims, France
[3] CHU Nice, Neurol, F-06202 Nice, France
[4] CHU Rennes, Neurol, Rennes, France
[5] CHU Toulouse, Neurol, Toulouse, France
[6] CHU Pitie Salpetriere, Neurol, Paris, France
[7] CHU Lyon, Neurol, Lyon, France
[8] CHU Strasbourg, Neurol, F-67000 Strasbourg, France
[9] CHU Nancy, Neurol, Nancy, France
[10] Fdn Ophtalmol A de Rothschild, Neurol, Paris, France
[11] CHU Clermont Ferrand, Neurol, Clermont Ferrand, France
[12] CHU Caen, Neurol, F-14000 Caen, France
[13] CHU Nantes, Neurol, F-44035 Nantes 01, France
[14] CHU Dijon, Neurol, Dijon, France
[15] CHU Montpellier, Neurol, Montpellier, France
[16] CHU Bordeaux, Neurol, Bordeaux, France
[17] Medday Pharmaceut, Paris, France
[18] CHU Marseille, Neurol, Marseille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
233
引用
收藏
页码：785 / 785
页数：1
相关论文
共 50 条
  • [1] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): subgroup analyses
    Laplaud, D. -A.
    Gout, O.
    Clavelou, P.
    Pelletier, J.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 402 - 403
  • [2] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): Subgroup Analyses
    Laplaud, David-Axel
    Gout, Olivier
    Clavelou, Pierre
    Pelletier, Jean
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 33 - 33
  • [3] MD1003 in progressive multiple sclerosis: 24-month brain MRI results of the MS-SPI trial
    Arnold, D.
    Ranjeva, J. -P.
    Pelletier, J.
    Barrilot, C.
    Jean, B.
    Galanaud, D.
    Pierot, L.
    Edan, G.
    Clavelou, P.
    Sedel, F.
    Tourbah, A.
    Berry, I.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 35 - 36
  • [4] MD1003 in Progressive Multiple Sclerosis: 24-Month Brain Volume Changes of the MS-SPI Trial
    Arnold, Douglas L.
    Ranjeva, Jean-Phillipe
    Pelletier, Jean
    Barillot, Christian
    Jean, Betty
    Galanaud, Damien
    Pierot, Laurent
    Papeix, Caroline
    Edan, Gilles
    Clavelou, Pierre
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Berry, Isabelle
    Morteau, Olivier
    Lasser, Robert
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 70 - 71
  • [5] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): EDSS sub-scores
    Papeix, C.
    Lebrun-Frenay, C.
    Defer, G.
    Labauge, P.
    Ruiz, M.
    Simon, O.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 938 - 939
  • [6] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): EDSS Sub-Scores
    Papeix, Caroline
    Lebrun-Frenay, Christine
    Defer, Gilles
    Laubage, Pierre
    Ruiz, Marta
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 34 - 34
  • [7] 24-Month-Treatment with-MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of the MS-SPI Trial Extension Phase
    Tourbah, Ayman
    Lebrun-Frenay, Christine
    Edan, Gilles
    Clane, Michel
    Papeix, Caroline
    Vukusic, Sandra
    De Seze, Jerome
    Debouverie, Marc
    Gout, Olivier
    Clavelou, Pierre
    Defer, Gilles
    Laplaud, David
    Moreau, Thibault
    Labauge, Pierre
    Brochet, Bruno
    Sedel, Frederic
    Pelletier, Jean
    [J]. NEUROLOGY, 2016, 86
  • [8] High doses of biotin in progressive multiple sclerosis: extension phase results of the MS-SPI trial
    Tourbah, A.
    Lebrun-Frenay, C.
    Edan, G.
    Clanet, M.
    Papeix, A. -C.
    Vukusic, S.
    de Seze, J.
    Debouverie, M.
    Gout, O.
    Clavelou, P.
    Defer, G. L.
    Laplaud, D.
    Moreau, T.
    Labauge, P.
    Brochet, B.
    Sedel, F.
    Pelletier, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 70 - 70
  • [9] Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis
    Saint Paul, Laure Peyro
    Debruyne, Daniele
    Bernard, Delphine
    Mock, Donald M.
    Defer, Gilles L.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 327 - 344
  • [10] Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS
    Cree, Bruce A. C.
    Cutter, Gary
    Wolinsky, Jerry S.
    Freedman, Mark S.
    Comi, Giancarlo
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Sedel, Frederic
    Lublin, Fred
    [J]. NEUROLOGY, 2020, 94 (15)
12345